Rybix Odt Patent Expiration

Rybix Odt is a drug owned by Shionogi Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 05, 2017. Details of Rybix Odt's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6106861 Multiparticulate tablet disintegrating in less than 40 seconds in the mouth
Dec, 2017

(7 years ago)

Expired
US5464632 Rapidly disintegratable multiparticular tablet
Mar, 2013

(11 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Rybix Odt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Rybix Odt's family patents as well as insights into ongoing legal events on those patents.

Rybix Odt's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Rybix Odt's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 05, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Rybix Odt Generic API suppliers:

Tramadol Hydrochloride is the generic name for the brand Rybix Odt. 28 different companies have already filed for the generic of Rybix Odt, with Sun Pharm having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Rybix Odt's generic

Alternative Brands for Rybix Odt

There are several other brand drugs using the same active ingredient (Tramadol Hydrochloride) as Rybix Odt. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Athena
Qdolo
Cipher Pharms Inc
Conzip
Janssen Pharms
Ultram
Kowa Pharms
Seglentis
Purdue Pharma
Ryzolt


Apart from brand drugs containing the same ingredient, some generics have also been filed for Tramadol Hydrochloride, Rybix Odt's active ingredient. Check the complete list of approved generic manufacturers for Rybix Odt





About Rybix Odt

Rybix Odt is a drug owned by Shionogi Inc. Rybix Odt uses Tramadol Hydrochloride as an active ingredient. Rybix Odt was launched by Shionogi Inc in 2005.

Approval Date:

Rybix Odt was approved by FDA for market use on 05 May, 2005.

Active Ingredient:

Rybix Odt uses Tramadol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Tramadol Hydrochloride ingredient

Dosage:

Rybix Odt is available in tablet, orally disintegrating form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG TABLET, ORALLY DISINTEGRATING Discontinued ORAL